-+ 0.00%
-+ 0.00%
-+ 0.00%

Ultragenyx Pharmaceutical (RARE) Gains MHRA Momentum, Is A 36% Undervaluation Enough?

Simply Wall St·11/18/2026 05:12:21
Listen to the news

The trigger for Ultragenyx Pharmaceutical (RARE) is the UK MHRA accepting its Marketing Authorisation Application for UX111, an investigational gene therapy for Sanfilippo syndrome Type A, alongside management’s 2027 profitability commentary.

Set against a 1 day share price return of 5.03% and a 30 day share price gain of 10.82%, Ultragenyx Pharmaceutical is still working through a sharp reset, with the 90 day share price return down 34.04% and the 1 year total shareholder return down 47.58%. The MHRA and EMA progress plus upcoming conference appearances therefore look more like a potential shift in sentiment than a completed turnaround.

Spot shifting sentiment in rare-disease biotech by lining up Ultragenyx Pharmaceutical against a curated 18 high quality undiscovered gems that may also be flying under most radars.

For Ultragenyx Pharmaceutical at about $16.70 after a sharp fall followed by a quick bounce, the trade-off is clear: step in after this UX111-driven move or wait to see if the reset becomes even cheaper as the valuation work shows.

Most Popular Narrative: 36% Undervalued

On the narrative view, Ultragenyx Pharmaceutical at $16.70 screens against a fair value of $26.00, which frames the current rebound as a potential discount rather than a full repricing. According to AnimalDoctorKwon, an investor in the Simply Wall St Community who wrote the narrative, the real question is whether that apparent value offsets what they see as deep structural friction in the model.

The "Ultragenyx Turnaround Thesis" is trapped in a commercial illusion, mistaking a multi-product portfolio for financial stability while ignoring deep-rooted structural inefficiencies.

Here is why the market is mispricing the friction inside RARE’s operational engine:

See why 2 investors see Ultragenyx Pharmaceutical as 36% undervalued.

Result: Fair Value of $26.00 (UNDERVALUED)

Still, the Ultragenyx Pharmaceutical bear case can unravel quickly if UX111 gains broader regulatory traction or if restructuring reduces operating losses faster than expected.

Find out about the key risks to this Ultragenyx Pharmaceutical narrative.

Next Steps

Mixed sentiment runs through Ultragenyx Pharmaceutical, with clear worries on one side and real upside arguments on the other. Investors should move quickly and weigh both the 2 key rewards and 3 important warning signs.

Looking for more investment ideas beyond Ultragenyx Pharmaceutical?

Do not stop at Ultragenyx Pharmaceutical. Use the same disciplined approach on a wider watchlist so you are not depending on a single biotech outcome.